1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Indivior Pharmaceuticals Inc

Indivior Pharmaceuticals Inc

INDV.L
Indivior Pharmaceuticals IncGB flagLondon Stock Exchange
1,238.00
GBp
+19.00
- -
1.54BMarket Cap
Indivior Pharmaceuticals Inc
INDV.L
(London Stock Exchange)

Recent

price

1,238.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
8.51
9.09
8.46
7.76
7.06
7.35
7.58
6.91
5.4
4.41
5.43
6.48
7.96
8.98
9.21
Revenue per Share
4.17
4.12
3.4
2.8
1.59
0.24
0.4
1.89
0.92
-1.01
1.41
-0.32
-0.94
0.02
1
Basic EPS, GAAP
4.68
5.86
5.48
2.88
2.01
2.58
1.75
1.8
0.99
-1.34
2.19
-0.06
-2.57
0.04
1.34
Free Cash Flow per Basic Share
- -
- -
1.66
3.48
0.16
0.48
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
1.72
0.98
8.55
5.82
7.23
7.1
7.65
9.54
10.47
9.44
10.35
9.86
-1.65
-2.96
-2.56
Book Value per Share
0.81
0.19
-1.11
-3.94
-2.37
-2.63
-2.05
-0.12
0.94
0.14
0.83
-0.14
-1.49
-2.68
-2.08
Tangible Book Value per Share
147
147
144
144
144
144
144
145
145
147
146
139
137
132
127
Basic Weighted Avg Shares
1,254
1,339
1,216
1,115
1,014
1,058
1,093
1,005
785
647
791
901
1,093
1,188
1,174
Sales/Revenue/Turnover
69.54
66.02
57.15
50.4
34.12
14.08
17.66
31.44
22.68
-24.11
22.88
23.86
22.23
19.19
37.05
Operating Margin (%)
25
27
28
26
32
14
13
16
28
26
22
16
15
29
28
Depreciation Expense
614
607
489
403
228
35
58
275
134
-148
205
-44
-129
2
128
Net Income, GAAP
29.59
31.33
29.64
28.16
20
64.29
57.66
1.08
25.56
- -
- -
- -
- -
78.57
37.5
Effective Tax Rate (%)
48.96
45.33
40.21
36.14
22.49
3.31
5.31
27.36
17.07
-22.87
25.92
-4.88
-11.8
0.17
10.9
Profit Margin (%)
24
-47
-223
103
118
-40
371
511
618
588
640
240
-24
-100
-105
Working Capital
- -
- -
- -
719
571
434
477
237
284
273
275
266
271
347
337
LT Debt
254
145
-66
-475
-279
-295
-203
66
209
82
203
51
-192
-348
-258
Total Equity
- -
309.69
- -
299.05
79.65
15.88
26.02
92.76
29.64
- -
- -
- -
- -
50.37
162.8
Return on Invested Capital (%)
- -
304.26
71.18
28.83
16.77
3.17
4.69
18.83
8.73
- -
- -
- -
- -
55.31
21.06
Return on Capital (%)
- -
304.26
71.18
39.03
24.32
3.4
5.46
22.07
9.21
-10.19
14.18
-3.06
0.15
- -
1.81
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
28
29
29
LT Borrowings
315
311
308
LT Finance Leases
32
30
29
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
125
125
125
Market Capitalization
169,613
121,181
189,728

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
839
883
951
Cash, Cash Equivalents & STI
320
373
510
Accounts Receivable, Net
254
243
240
Inventories
178
163
149
Total Current Liabilities
939
1,005
1,056
Payables & Accruals
- -
- -
- -
ST Debt
28
29
29
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-36.59%
-76.66%
81.25%
Free Cash Flow
304.44%
623.85%
-101.42%
Net Income, GAAP
-21.83%
-95.76%
-101.55%
Sales/Revenue/Turnover
1.72%
9.72%
8.69%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
253
276
271
293
1,093
2024
284
299
307
299
1,188
2025
266
302
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
0.32
0.28
-0.98
0.39
-0.94
2024
0.45
-0.72
0.03
0.47
0.02
2025
0.38
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Aion Therapeutic Inc. (AION.CN)
Rapid Nutrition PLC (ALRPD.PA)
Alkem Laboratories Limited (ALKEM.BO)
Honz Pharmaceutical Co., Ltd. (300086.SZ)
Aurora Cannabis Inc. R (21P.F)
Millennium Sustainable Ventures Corp. (MILC)
Business
Indivior PLC is a global pharmaceutical innovator dedicated to pioneering life-transforming treatments for substance use disorders and other serious mental illnesses. The company primarily develops, manufactures, and commercializes buprenorphine-based prescription medications designed to address opioid dependence. Its core product portfolio includes SUBLOCADE, a monthly extended-release buprenorphine injection, and SUBOXONE, available in sublingual film and tablet forms, both critical for opioid use disorder treatment. Additionally, Indivior offers Perseris, an extended-release injectable for schizophrenia, and OPVEE nasal spray for opioid overdose reversal. Indivior maintains a robust development pipeline, focusing on expanding its offerings for addiction and other related conditions. Headquartered in North Chesterfield, Virginia, the company operates across numerous countries worldwide, emphasizing a patient-centric approach and a mission to transform addiction into a recognized and treatable chronic disease. The company recently completed its redomiciliation to the U.S. and delisted from the London Stock Exchange in July 2025, consolidating its primary listing on Nasdaq. Indivior also successfully resolved a legacy U.S. Department of Justice matter in November 2025.